br101801
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04018248)
Timeline
Indications
Studied for
- Cholesterol · Phase 1
- Essential Hypertension · Phase 3
- Hypercholesterolemia · Phase 3
- Hypertension · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Myc proto-oncogene proteinINHIBITOR
MYC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07180771 | Phase 2 | Sep 30, 2025 | Boryung Pharmaceutical Company |
| NCT06889012 | Phase 1 | May 7, 2025 | Boryung Pharmaceutical Company |
| NCT06165250 | Phase 3 | Dec 31, 2023 | Boryung Pharmaceutical Company |
| NCT05460364 | Phase 1 | Jun 30, 2022 | Boryung Pharmaceutical Company |
| NCT04018248 | Phase 1 | Nov 30, 2019 | Boryung Pharmaceutical Company, Seoul National University, Sungkyunkwan University, University of Ulsan |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Company | For profit | 5 | 5 | 3 | 2019 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1